Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 11/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897483 | 1.00 | HTR6 (0.48) | HTR6ALDH1A1MEN1KMT2AKDM4C | |
| SCHEMBL3904998 | 0.84 | HTR6 (0.57) | HTR6KDM4C | |
| SCHEMBL3905003 | 0.84 | HTR6 (0.57) | HTR6KDM4C | |
| SCHEMBL3911781 | 0.84 | HTR6 (0.46) | HTR6ALDH1A1MEN1KMT2AKDM4C | |
| SCHEMBL3911777 | 0.84 | HTR6 (0.46) | HTR6ALDH1A1MEN1KMT2AKDM4C | |
| SCHEMBL316011 | 0.79 | HTR6 (0.49) | HTR6 | |
| SCHEMBL316010 | 0.79 | HTR6 (0.49) | HTR6 | |
| SCHEMBL14320432 | 0.77 | HTR6 (0.59) | HTR6 | |
| SCHEMBL3903865 | 0.77 | HTR6 (0.59) | HTR6 | |
| SCHEMBL6491979 | 0.74 | MTNR1A (0.46) | ALDH1A1MEN1KMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2076489-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147762-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | HTR6, TPH1, HTR1B | HTR6 1/4885ALDH1A1 737/4885MEN1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.